Loading
Life sciences · Journal article
Bmemat · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Postoperative recurrence remains a critical challenge in cancer management, necessitating innovative strategies to reshape the tumor microenvironment (TME) and enhance immune surveillance. This review highlights nanomedicine‐driven breakthroughs in postoperative immunotherapy, emphasizing their potential to overcome immunosuppressive TME and enable precision delivery. By integrating stimulus‐responsive release, multifunctional targeting, and biomimetic designs, nanotherapeutics enhance the efficacy of immune checkpoint blockade, adoptive cell therapy, and tumor vaccines while reducing systemic toxicity. Notably, advanced nanoplatforms remodel the TME by alleviating hypoxia, normalizing vasculature, and reprogramming immunosuppressive cells. Emerging innovations, including injectable hydrogels, implantable nanodevices, and localized photo/sonodynamic therapies provide sustained immunomodulation at resection sites, effectively suppressing residual tumors and preventing metastasis. Furthermore, nanovaccines leveraging autologous tumor antigens and AI‐driven personalization achieve improved lymph node targeting and durable immune memory. The convergence of nanotechnology with gene editing and real‐time monitoring underscores its versatility in addressing clinical challenges, such as drug resistance and recurrence heterogeneity. Overall, this work underscores a paradigm shift toward nanomedicine‐enabled precision immunotherapy, offering a robust framework to improve postoperative outcomes and long‐term survival in cancer patients.